Abstract P3-08-10: Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER+/HER-, lymph node negative breast cancer
Sarah Sammons(Dana-Farber Cancer Institute), Rachel A. Greenup(Yale University), Carey K. Anders(Duke University), Jennifer K. Plichta(Cancer Institute (WIA)), Susan Dent(Government of the United States of America), Samantha M. Thomas(Duke University), Oluwadamilola M. Fayanju(Penn Center for AIDS Research), Gretchen Kimmick(Johns Hopkins University), Terry Hyslop(Thomas Jefferson University), Kelly Westbrook(Duke Medical Center), E. Shelley Hwang(Duke University), Jeremy Force(Daiichi Sankyo (Germany)), Laura H. Rosenberger(Duke University), Yi Ren(Duke University), P. Kelly Marcom(Duke University)
Cited by 3
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991